{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-001955","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.909539+00:00","generated_at":"2026-05-16T10:38:30.348200+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Precision BioSciences reports ~$137M cash, outlines 2026 clinical milestones for HBV and DMD programs","bullets":["Preliminary cash ~$137M as of Dec 31, 2025; cash runway expected through 2028.","PBGENE-HBV: Phase 1/2a ELIMINATE-B dosing Cohorts 3-5 ongoing; additional biopsy data expected H1 2026.","PBGENE-DMD: IND clearance expected Q1 2026; first patient dosing late-Q1/early-Q2 2026; initial data by year-end 2026.","Partnered programs: iECURE ECUR-506 RMAT designation; Imugene milestone $8M received; TG Therapeutics potential $7.5M milestone."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-001955","json":"https://secwatch.observer/filing/0001628280-26-001955.json","markdown":"https://secwatch.observer/filing/0001628280-26-001955.md","text":"https://secwatch.observer/filing/0001628280-26-001955.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026001955/0001628280-26-001955-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026001955/dtil-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:38:30.348200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}